Human FactorsNICU-TACNCT06659978
Human Factors Validation and Acceptability Testing of a Stimulation Device
An observational study of Human Factors and Acceptability, run by University of Liverpool at 3 sites in United Kingdom.
Trial summary
Our team have developed a mattress topper, consisting of rubber tubes attached side to side that are deflated and inflated, mimicking dynamic touch and optimal CT stimulation (3cm/s). It is connected to a microprocessor control unit and a vacuum supply. Read more about this study
- Who is it for?
- Ages 34 to 42 weeks
- Conditions the study is for
- Human Factors, Acceptability, Tolerance
- What is being tested?
- Device tolerance and Acceptability questionnaire
- Type of treatment
- Medical device
- How many people
- 34 participants
- Where
- 3 sitesUnited Kingdom
- Study dates
- 5 Jan 2024to 2 Feb 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 34 to 42 weeks
- All sexes
- No healthy volunteers
- Child
Study population: Well infant born between 34 and 42 weeks in the low dependency unit or postnatal ward.
Who may be able to join
- Infant is born between 34- and 42-weeks gestational age.
- Infant an in-patient at LWH based on the low dependency unit or post-natal ward.
- Infant is born from a low-risk pregnancy with no concerns identified antenatally or postnatally.
- Infant has been identified as eligible by neonatal clinician (junior doctor or advanced neonatal nurse practitioner).
- Written consent has been obtained from the person(s) with parental responsibility.
- Infant has been normoglycaemic since birth or for at least 24 hours.
Who cannot join
- Known genetic condition or undergoing investigation for a suspected genetic condition.
- Previously admitted to high dependency or intensive care.
- Has received invasive respiratory support.
- Has received any treatment for seizures.
- Is receiving phototherapy.
- Is receiving caffeine.
Show all 9Show fewer
- Concerns about feeding (e.g., a condition that may interfere with feeding such as cleft palate or any tube feeding at the time of the study) NB tongue tie is NOT an exclusion criterion.
- Needing any support for thermoregulation (in incubator or using "hot cot")
- Clinical instability in the judgment of nurses/midwives and paediatricians looking after the baby and mother.
Trial locations and contacts
3 sites in 1 country.
United Kingdom3 sites
Liverpool John Moores University
Liverpool, L3 3AF
Liverpool Womens Hospital Trust
Liverpool, L8 7SS
University of Liverpool
Liverpool
About this study
Official title: Missing Touch 1: Human Factors Validation and Acceptability Testing of a Neuro-engineered C-tactile Stimulation Device
Our team have developed a mattress topper, consisting of rubber tubes attached side to side that are deflated and inflated, mimicking dynamic touch and optimal CT stimulation (3cm/s). It is connected to a microprocessor control unit and a vacuum supply. By controlling the interval between the vacuum applied to each tube in the device it generates a flow sequence as each tube relaxes back to its original state. This will feel like a stroking across the skin - but non-frictional, thereby minimising the risk of friction related skin damage.
The device is placed on top of a standard mattress in a neonatal cot. It has been manufactured in line with European Union (EU) safety requirements. It has been calibrated to mimic optimal CT fibre activation at 3cm/s, in line with previous touch intervention studies (Gursul et al., 2018; Manzotti et al., 2019). The device is made from silicone and is fully waterproof. A cleaning protocol will be implemented between each use for infection control. The waterproof sheet will be covered by a standard cot sheet.
Read the detailed description
New-born infants are subject to several novel experiences that cause physiological, biochemical and behavioural indicators of stress; even routine and common events such as handling, changing a diaper or being bathed can induce a stress response. Tactile interventions such as skin-to-skin touch and 'still containment hold' are widely used in clinical care with apparent positive results, such as lower mean respiratory heart rate and pain measures, and higher oxygen saturation (Boundy et al., 2016; Pineda et al., 2017); yet, dynamic touch interventions have reported to be more beneficial than static touch interventions (Field, Diego, Hernandez-Reif, Deeds, \& Figuereido, 2006; Manzotti et al., 2019; Vickers, Ohlsson, Lacy, \& Horsley, 2004).
A distinct class of unmyelinated C-fibre sensory neurons called C-tactile afferents (CT), found exclusively in the hairy skin of the body, that respond optimally to gentle stroking touch at a velocity of ~3cm/s, are hypothesised to process the pleasant and social rewarding properties of touch (Olausson et al., 2010, McGlone et al., 2014). CT fibre activation also plays a role in pain inhibition (Gursul et al., 2018; Habig et al., 2017; Liljencrantz et al., 2017) and may also be linked to the development of self-regulation (Van Puyvelde, Gorissen, Pattyn, \& McGlone, 2019), thereby serving a neuroprotective function for the developing infant brain.
Touch induced-analgesia such as skin-to-skin contact and breastfeeding are also considered as standard care non-pharmacological interventions for procedural pain in infants (Campbell-Yeo et al., 2019; Chang, Filoteo, \& Nasr, 2020). However, dynamic touch is not currently acknowledged as a non-pharmacological intervention in the UK.
Touch is the first sense to develop in utero at approximately 8-weeks gestational age and is the most mature sense postnatally (Marx \& Nagy, 2015). The benefits of touch are now widely recognised in postnatal care with the World Health Organization (2019) recommending that term infants engage in skin-to-skin contact with their mother or carer for at least an hour after birth due to the physiological benefits for both infant and mother.
There is limited research into the underlying mechanism behind the physiological benefits of touch, either in-utero or post-partum; however, it is hypothesised that foetal movements cause the amniotic fluid to elicit movement of lanugo (fine hair), which activates specific nerve fibres - C-Tactile afferents (CTs) to facilitate growth regulation (Bystrova, 2009).
CTs signal the affective component of touch (Löken, Wessberg, Morrison, McGlone, \& Olausson, 2009; McGlone, Cerritelli, Walker, \& Esteves, 2017). Found exclusively in hairy skin they project to the insular cortex (Olausson et al., 2002), part of the brain's self-regulation system and associated with emotional processing (Dalgleish, 2004). Microneurography, a method employed to visualise and record the traffic of nerve impulses, from CTs find that they respond optimally to low force and velocity dynamic touch delivered at ~ 3cm/sec at skin temperature (Löken et al., 2009), supporting the hypothesis of the social function for the nerve in nurture, grooming and affiliative behaviours.
A recent study carried out with preterm infants in a Neonatal Intensive Care Unit (NICU) found that dynamic touch, delivered at CT optimal speed, reduced heart rate and increased blood oxygenation levels in neonates (Manzotti et al., 2019). Should the hypothesis be accepted in this study it will offer insight into some of the mechanisms behind the physiological advantages of touch, leading to the improvement of neurodevelopmental outcomes for newborns e.g., during painful procedures. However, there are instances where infants are deprived of touch, such as lack of skin integrity and risk of infections, lack of parental presence and disorders such as foetal alcohol syndrome or neonatal abstinence syndrome. This series of studies is aimed at individuals who are deprived of touch - it is not seen as a replacement for maternal/carer touch.
Here we will investigate the tolerability of the device-delivered tactile stimulation at CT-optimal velocity by measuring physiological indicators of stress in infants, as determined by heart rate and blood oxygenation, and assessment of stress behaviours.
- Conditions
- Human Factors, Acceptability, Tolerance
- Being tested
- Device tolerance, Acceptability questionnaire
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Device toleranceDevice
After being fed (breastmilk or formula), video will be turned on and the infant is placed on the Gentle Touch Stimulator (GTS) in deactivated mode. After a baseline period of 5- minutes the device will be activated. It will be deactivated after 10 minutes or earlier if there are any signs of distress from the infant. A 10-minute washout observation period will be followed.
Higher levels of comfort will be considered as fewer instances of stress behaviours. The sessions will be videoed, and coded at a later date using Observation of infant behaviours.
Acceptability questionnaireOther
Parental and clinical staff acceptability of the device assessed by interviewing person(s) of parental responsibility and clinicians involved in the trial. Interviews will be conducted by researcher following the intervention.
| Study group | Role | What they receive |
|---|---|---|
| Infants | Well, infants born between 34 and 42 weeks. Receives: Device: Device tolerance; Other: Acceptability questionnaire |
What is being measured
The primary outcome is the main question the study is designed to answer.
Infant device tolerance
Infant's physiological responses to the device are measured by heart rate and blood oxygenation
Measured: 25 minutes
Secondary outcomes (2)
Infant comfort levels
Higher levels of comfort will be considered as fewer instances of stress behaviours. The sessions will be videoed, and coded at a later date using Observation of infant behaviours.
Measured: 25 minutes
Parental and clinical staff acceptability
Assessed by interviewing person(s) of parental responsibility and clinicians involved in the trial
Measured: 15 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Oct 2024
- Study start5 Jan 2024
- Primary completion30 Apr 2024
- Study completion2 Feb 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Human FactorsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 34 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Liverpool
- Sponsor type
- University, hospital or other
- Collaborators
- Liverpool John Moores University, Liverpool Women's NHS Foundation Trust
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06659978
- Sponsor's protocol ID
- UoL001661
- Acronym
- NICU-TAC
- Status last verified
- Apr 2025
- First submitted
- 24 Oct 2024
- Last updated
- 22 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Missing Touch 1: Human Factors Validation and Acceptability Testing of a Neuro-engineered C-tactile Stimulation Device
- ClinicalTrials.gov ID
- NCT06659978
- Acronym / sponsor ID
- NICU-TAC / UoL001661
- Conditions
- Human Factors, Acceptability, Tolerance
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 34 participants (actual)
- Lead sponsor
- University of LiverpoolUniversity, hospital or other
- Collaborators
- Liverpool John Moores University, Liverpool Women's NHS Foundation Trust
- Study start
- 5 Jan 2024 (actual)
- Primary completion
- 30 Apr 2024 (actual)
- Study completion
- 2 Feb 2025 (actual)
- First posted
- 26 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Our team have developed a mattress topper, consisting of rubber tubes attached side to side that are deflated and inflated, mimicking dynamic touch and optimal CT stimulation (3cm/s). It is connected to a microprocessor control unit and a vacuum supply. By controlling the interval between the vacuum applied to each tube in the device it generates a flow sequence as each tube relaxes back to its original state. This will feel like a stroking across the skin - but non-frictional, thereby minimising the risk of friction related skin damage.
The device is placed on top of a standard mattress in a neonatal cot. It has been manufactured in line with European Union (EU) safety requirements. It has been calibrated to mimic optimal CT fibre activation at 3cm/s, in line with previous touch intervention studies (Gursul et al., 2018; Manzotti et al., 2019). The device is made from silicone and is fully waterproof. A cleaning protocol will be implemented between each use for infection control. The waterproof sheet will be covered by a standard cot sheet.
Detailed description
New-born infants are subject to several novel experiences that cause physiological, biochemical and behavioural indicators of stress; even routine and common events such as handling, changing a diaper or being bathed can induce a stress response. Tactile interventions such as skin-to-skin touch and 'still containment hold' are widely used in clinical care with apparent positive results, such as lower mean respiratory heart rate and pain measures, and higher oxygen saturation (Boundy et al., 2016; Pineda et al., 2017); yet, dynamic touch interventions have reported to be more beneficial than static touch interventions (Field, Diego, Hernandez-Reif, Deeds, \& Figuereido, 2006; Manzotti et al., 2019; Vickers, Ohlsson, Lacy, \& Horsley, 2004).
A distinct class of unmyelinated C-fibre sensory neurons called C-tactile afferents (CT), found exclusively in the hairy skin of the body, that respond optimally to gentle stroking touch at a velocity of ~3cm/s, are hypothesised to process the pleasant and social rewarding properties of touch (Olausson et al., 2010, McGlone et al., 2014). CT fibre activation also plays a role in pain inhibition (Gursul et al., 2018; Habig et al., 2017; Liljencrantz et al., 2017) and may also be linked to the development of self-regulation (Van Puyvelde, Gorissen, Pattyn, \& McGlone, 2019), thereby serving a neuroprotective function for the developing infant brain.
Touch induced-analgesia such as skin-to-skin contact and breastfeeding are also considered as standard care non-pharmacological interventions for procedural pain in infants (Campbell-Yeo et al., 2019; Chang, Filoteo, \& Nasr, 2020). However, dynamic touch is not currently acknowledged as a non-pharmacological intervention in the UK.
Touch is the first sense to develop in utero at approximately 8-weeks gestational age and is the most mature sense postnatally (Marx \& Nagy, 2015). The benefits of touch are now widely recognised in postnatal care with the World Health Organization (2019) recommending that term infants engage in skin-to-skin contact with their mother or carer for at least an hour after birth due to the physiological benefits for both infant and mother.
There is limited research into the underlying mechanism behind the physiological benefits of touch, either in-utero or post-partum; however, it is hypothesised that foetal movements cause the amniotic fluid to elicit movement of lanugo (fine hair), which activates specific nerve fibres - C-Tactile afferents (CTs) to facilitate growth regulation (Bystrova, 2009).
CTs signal the affective component of touch (Löken, Wessberg, Morrison, McGlone, \& Olausson, 2009; McGlone, Cerritelli, Walker, \& Esteves, 2017). Found exclusively in hairy skin they project to the insular cortex (Olausson et al., 2002), part of the brain's self-regulation system and associated with emotional processing (Dalgleish, 2004). Microneurography, a method employed to visualise and record the traffic of nerve impulses, from CTs find that they respond optimally to low force and velocity dynamic touch delivered at ~ 3cm/sec at skin temperature (Löken et al., 2009), supporting the hypothesis of the social function for the nerve in nurture, grooming and affiliative behaviours.
A recent study carried out with preterm infants in a Neonatal Intensive Care Unit (NICU) found that dynamic touch, delivered at CT optimal speed, reduced heart rate and increased blood oxygenation levels in neonates (Manzotti et al., 2019). Should the hypothesis be accepted in this study it will offer insight into some of the mechanisms behind the physiological advantages of touch, leading to the improvement of neurodevelopmental outcomes for newborns e.g., during painful procedures. However, there are instances where infants are deprived of touch, such as lack of skin integrity and risk of infections, lack of parental presence and disorders such as foetal alcohol syndrome or neonatal abstinence syndrome. This series of studies is aimed at individuals who are deprived of touch - it is not seen as a replacement for maternal/carer touch.
Here we will investigate the tolerability of the device-delivered tactile stimulation at CT-optimal velocity by measuring physiological indicators of stress in infants, as determined by heart rate and blood oxygenation, and assessment of stress behaviours.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Infants | – | Device: Device tolerance, Other: Acceptability questionnaireWell, infants born between 34 and 42 weeks. |
Who may qualify
- Ages
- 34 to 42 weeks
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
- Study population
- Well infant born between 34 and 42 weeks in the low dependency unit or postnatal ward.
Key inclusion criteria (6 listed)
- Infant is born between 34- and 42-weeks gestational age.
- Infant an in-patient at LWH based on the low dependency unit or post-natal ward.
- Infant is born from a low-risk pregnancy with no concerns identified antenatally or postnatally.
- Infant has been identified as eligible by neonatal clinician (junior doctor or advanced neonatal nurse practitioner).
- Written consent has been obtained from the person(s) with parental responsibility.
Key exclusion criteria (9 listed)
- Known genetic condition or undergoing investigation for a suspected genetic condition.
- Previously admitted to high dependency or intensive care.
- Has received invasive respiratory support.
- Has received any treatment for seizures.
- Is receiving phototherapy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Device toleranceAfter being fed (breastmilk or formula), video will be turned on and the infant is placed on the Gentle Touch Stimulator (GTS) in deactivated mode. After a baseline period of 5- minutes the device will be activated. It will be deactivated after 10 minutes or earlier if there are any signs of distress from the infant. A 10-minute washout observation period will be followed. Higher levels of comfort will be considered as fewer instances of stress behaviours. The sessions will be videoed, and coded at a later date using Observation of infant behaviours. | Device | Infants |
| Acceptability questionnaireParental and clinical staff acceptability of the device assessed by interviewing person(s) of parental responsibility and clinicians involved in the trial. Interviews will be conducted by researcher following the intervention. | Other | Infants |
Primary outcome
Infant device tolerance
Time frame: 25 minutes
Infant's physiological responses to the device are measured by heart rate and blood oxygenation
2 secondary outcomes
Infant comfort levels
Time frame: 25 minutes
Parental and clinical staff acceptability
Time frame: 15 minutes
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Apr 2025.
- Individual participant dataSharing planned: No
Related trials for Human Factors
Enrolling by invitationObservational study
A Study of VAX-ID® 2200, a New Device for Intradermal Injections
Sharps Injuries
RecruitingObservational study
Study of Factors Regulating Mast Cell Proliferation
Mastocytosis, Monoclonal
RecruitingObservational study
Operating-Room Distractions, Surgeon Workload, Anxiety, Teamwork and Intraoperative Adverse Events (ORCHESTRA)
Colorectal Diseases, Anal Diseases
Not yet recruitingObservational study
Assessment of the Acceptability of, and Factors Associated With, Recommended Vaccinations During Pregnancy in Maternity Units in the Ile-de-France Region
Vaccination Coverage Among Pregnant Women
RecruitingPhase 1/2
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Advanced/Metastatic Solid Tumors, Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Human Factors and Acceptability, run by University of Liverpool at 3 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Infant device tolerance (time frame: 25 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Apr 2025.